{"title":"Height and Body Mass Index Changes in Chinese Children Undergoing Chemotherapy for Acute Lymphoblastic Leukemia.","authors":"Yixiao Chen, Jing Miao, Xinyi Liang, Jingying Zhang, Weiqun Xu, Hua Song, Yongmin Tang, Junfen Fu, Xiaojun Xu","doi":"10.1080/01635581.2025.2505261","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Children with acute lymphoblastic leukemia (ALL) have a higher risk of height deficit and obesity. Data on Chinese pediatric ALL patients treated on chemotherapy only are limited.</p><p><strong>Methods: </strong>Changes in z scores for height and body mass index (BMI) from the diagnosis to 2 years after the initial of treatment were analyzed in 805 ALL patients diagnosed at Children's Hospital of Zhejiang University School of Medicine.</p><p><strong>Results: </strong>A significant reduction in height z-scores and increase in BMI z-scores were documented during treatment (<i>p</i> < 0.001), the most pronounced changes observed in the first three months. Catch-up growth was noted after nine months. Children in middle-high-aged group showed the most significant decline in height z-scores after 24 months (<i>p</i> < 0.05). High-risk patients exhibited lower height z-scores at 9 and 12 months (<i>p</i> < 0.01). Children under 9 years or in non-high-risk group showed greater BMI z-scores increase during treatment (<i>p</i> < 0.05). There were no significant differences by gender.</p><p><strong>Conclusion: </strong>Chemotherapy leads to height deficit and BMI increase in pediatric ALL patients. Height deficit is more pronounced in children aged 8-13 years, BMI increases are more significant in younger children. High-risk patients are more prone to lower height and smaller BMI increases.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"1-10"},"PeriodicalIF":2.0000,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrition and Cancer-An International Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/01635581.2025.2505261","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Children with acute lymphoblastic leukemia (ALL) have a higher risk of height deficit and obesity. Data on Chinese pediatric ALL patients treated on chemotherapy only are limited.
Methods: Changes in z scores for height and body mass index (BMI) from the diagnosis to 2 years after the initial of treatment were analyzed in 805 ALL patients diagnosed at Children's Hospital of Zhejiang University School of Medicine.
Results: A significant reduction in height z-scores and increase in BMI z-scores were documented during treatment (p < 0.001), the most pronounced changes observed in the first three months. Catch-up growth was noted after nine months. Children in middle-high-aged group showed the most significant decline in height z-scores after 24 months (p < 0.05). High-risk patients exhibited lower height z-scores at 9 and 12 months (p < 0.01). Children under 9 years or in non-high-risk group showed greater BMI z-scores increase during treatment (p < 0.05). There were no significant differences by gender.
Conclusion: Chemotherapy leads to height deficit and BMI increase in pediatric ALL patients. Height deficit is more pronounced in children aged 8-13 years, BMI increases are more significant in younger children. High-risk patients are more prone to lower height and smaller BMI increases.
背景:急性淋巴细胞白血病(ALL)患儿有较高的身高缺陷和肥胖风险。仅接受化疗的中国儿科ALL患者的数据有限。方法:分析浙江大学医学院附属儿童医院诊断的805例ALL患者的身高、体重指数(BMI) z评分自诊断至治疗后2年的变化。结果:在治疗期间,身高z分数显著降低,BMI z分数显著升高(p p p p)。结论:化疗导致儿童ALL患者身高不足和BMI升高。身高不足在8-13岁的儿童中更为明显,年龄更小的儿童体重指数增加更为明显。高危患者更容易出现低身高和较小的BMI增加。
期刊介绍:
This timely publication reports and reviews current findings on the effects of nutrition on the etiology, therapy, and prevention of cancer. Etiological issues include clinical and experimental research in nutrition, carcinogenesis, epidemiology, biochemistry, and molecular biology. Coverage of therapy focuses on research in clinical nutrition and oncology, dietetics, and bioengineering. Prevention approaches include public health recommendations, preventative medicine, behavior modification, education, functional foods, and agricultural and food production policies.